Cited by 102Acute Ischemic Stroke ManagementNeurological Disorders and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Minocycline development for acute ischemic stroke

Open access
Fagan, Susan C., Cronic, Lydia E., Hess, David C.·2011·Translational Stroke Research

Abstract

Minocycline, a tetracycline antibiotic, has shown anti-inflammatory, anti-apoptotic, and neuroprotective effects in many models of cerebral ischemia and neurodegenerative disease. Its high penetration of the blood-brain barrier, good safety profile, and delayed therapeutic window make it an ideal candidate for use in stroke. In animal models, minocycline reduced infarct size and improved neurologic outcome when administered acutely, with similar neuroprotective benefits seen following delayed administration. To date, two early phase clinical trials have shown minocycline to be safe and potentially effective in acute ischemic stroke, alone or in combination with tissue plasminogen activator. A large efficacy clinical trial is now needed to confirm previous studies, allow for subgroup analysis, and pinpoint the potential place for minocycline in acute stroke therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12975-011-0072-6

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Minocycline has been incorporated into two clinical trials involving ischemic stroke patients, demonstrating that minocycline administration (both alone and in combination with fibrinolysis) improved neurological functional outcome following stroke.

    “So far, minocycline has been incorporated into two clinical trials involving ischemic stroke patients, demonstrating that minocycline administration (both alone and in combination with Fibrinolysis) improved neurological functional outcome following stroke (Fagan et al., 2011).”

    From The impact of microglial activation on blood-brain barrier in brain diseases (2014) · cites this paper as Fagan et al., 2011

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Fagan, S. C., Cronic, L. E., & Hess, D. C.
Affiliations
University of Georgia (US)
Corresponding author
Fagan, Susan C.
Venue
Translational Stroke Research
Published
2011-04-13
Volume
2
Issue
2
Pages
202-208
ISSN
  • 1868-4483 (ISSN-L)
  • 1868-601X
OpenAlex
W2019475666
Cited by
100
References
53
Citations by year
2026: 2 · 2024: 5 · 2023: 6 · 2022: 7 · 2021: 3 · 2020: 9 · 2019: 5 · 2018: 8 · 2017: 6 · 2016: 7 · 2015: 8 · 2014: 7 · 2013: 15 · 2012: 10
FWCI
8.19
Type
journal article
Language
en
Open access
Locations
  • Translational Stroke Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Neurological Disorders and Stroke (R01NS063965, R01NS055728)
Topics
  • Health Sciences › Medicine › Epidemiology › Acute Ischemic Stroke Management
  • Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
minocycline, acute ischemic stroke, neuroprotection, anti-inflammatory activity, anti-apoptotic effects, blood-brain barrier penetration, infarct size, tissue plasminogen activator, clinical trials, drug development

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review